46 results about "Gastro-" patented technology

The object of the invention relates to a coated pellet that is suitable for the manufacture of a pharmaceutical preparation and / or food supplement containing sodium bicarbonate, and that contains at least two coating layers. The coated pellet contains sodium bicarbonate as the only active ingredient, where the one coating layer is the intermediate insulating coating surrounding the pellet, and the other coating layer is the gastro-resistant coating surrounding the intermediate insulating coating, which gastro-resistant coating contains shellac or anionic methacrylate copolymer dissolving in an aqueous medium over a pH of 7. 0. Furthermore, the invention relates to the manufacture of the coated pellet, to pharmaceutical preparations and food supplements containing such coated pellet and to the use thereof.

The invention discloses a gastric retention double-layer sustained-release tablet and a preparation method and application thereof, and belongs to the field of pharmaceutical preparations, the active ingredient of the gastric retention double-layer sustained-release tablet is 3-[4-[4-(lH-benzotriazole-1-yl) butyl] piperazine-1-yl] benzisothiazole hydrochloride, and the gastric retention double-layer sustained-release tablet is composed of a quick-release drug release layer and a sustained-release drug release layer, the quick release layer contains an active component, a filler I and a disintegrating agent; and the sustained-release layer contains an active component, a filler II, an expansion material, a release retardant, an expansion accelerator and a stabilizer. According to the gastro-retention double-layer sustained-release tablet, the quick-release layer can quickly release the medicine to reach the effective blood concentration, and the retention time of the tablet in the stomach is prolonged after the sustained-release layer expands, so that the in-vivo absorption window of the medicine is prolonged, the maintenance of the blood concentration is realized, the in-vivo half-life period of active ingredients is remarkably prolonged, the administration frequency can be reduced, and the compliance of a patient is improved. The product is simple in preparation process, suitable for industrial production and wide in development prospect.

The present disclosure relates to an apparatus and a method for a laser treatment of gastro-esophageal reflux disease using a balloon catheter.

A gastro-resistant high-strength unit dosage form includes a solid solution prepared by hot-melt extrusion, whereby the solid solution contains 300 mg posaconazole and an enteric polymer in a specific weight ratio. The unit dosage form may be a capsule or an optionally film-coated tablet.

The invention relates to floating drug delivery systems (FDDS) that provide solutions to the particular problems often encountered with floating drug delivery systems described in the art. On such generally recognized problem is the vulnerability of the systems, especially damage to the gas-filled compartment making it accessible to water so as to impair its buoyancy, ultimately resulting in insufficient gastric residence time. The invention, in an aspect, provides a self-repairing FDDS that maintains its floating capacity after damaging. The floating drug delivery systems of the invention, furthermore, allow for incorporation of high loads of active ingredients. The floating drug delivery systems can be designed in such a way that release of active ingredient from the system occurs entirely independent from the pH of the fluid surrounding the system. Furthermore, the procedure of manufacturing the floating drug delivery system of the invention is simple and straightforward, and therefore economically attractive.

An orally administrable drug powder composition which forms a gastro-retentive RAFT having at least two trigger pulses is provide. The composition contains, at a minimum, (a) at least one GHB drug in a first pulse release which releases in less than about 3 hours; (b) at least one GHB drug in a delayed trigger release form; (c) at least one non-toxic gas generating agent; and (d) a RAFT system, wherein following oral ingestion, the composition provides a self-assembling gastro-retentive RAFT having entrapped therein, the at least one drug of (a) and (b) and the gas generated in situ by the non-toxic gas generating agent, thereby providing a floating gastro-retentive RAFT having a dual pulse system wherein at least the second pulse is a trigger pulse and which retains the at least one GHB drug in the stomach for at least about 3 hours.

An orally administrable drug powder composition which forms a gastro-retentive RAFT having at least two trigger pulses is provided. The composition contains, at a minimum, (a) at least one drug in an immediate release pulse release form; (b) at least one drug in a delayed trigger release form; (c) at least one non-toxic gas generating agent and (d) a RAFT system, wherein following oral ingestion, the composition provides a self-assembling gastro-retentive RAFT having entrapped therein, the at least one drug of (a) and (b) and the gas generated in situ by the non-toxic gas generating agent, thereby providing a floating gastro-retentive RAFT having a dual pulse system wherein at least the second pulse is a trigger pulse and which retains the at least one drug in the stomach for at least about 3 hours, provided that the composition does not include a gamma hydroxybutyrate and its salts, hydrates, tautomers, or solvates, or complexes thereof.

The invention is directed to a delivery device (10) for introducing and / or deploying an implant (12, 107) within the gastro-intestinal tract. The implant may be a bypass sleeve. The delivery device comprises a shaft assembly (24) with a longitudinal axis (L) and has an atraumatic tip component (26, 102) arranged at a distal end of the shaft assembly (24).

The invention relates to a predictive gene expression signature of response to antiangiogenic drugs, such as axitinib, in gastro-enteric-pancreatic and pulmonary neuroendocrine tumours. The signature is formed by the gene expression of three genes (SPP1, ATXN7 and REXO1L2P), which is converted by means of a bioinformation packet into a unique score that can predict which patients will benefit from treatment with the drug, this benefit being understood as longer survival without progression and larger tumour volume reductions in response to treatment.

The present invention relates to provide a novel, long term stable gastro resistant capsule composition comprising ferrous glycine sulfate. The invention further relates to methods of using the pharmaceutical compositions to treat iron deficiency anemia and related disorders.

The purpose of the present invention is to provide a novel composition for promoting the secretion of galactotropin. According to the present invention, provided is a composition for promoting secretion of gastro-somatotropin, which contains, as an active ingredient, one or more substances selected from the group consisting of oleic acid and acylglycerols containing palmitic acid and / or oleic acid as constituent fatty acids. The composition is preferably a composition for promoting appetite, improving inappetence, promoting secretion of growth hormone, improving low nutrition, promoting fat accumulation, increasing body weight, enhancing gastric acid secretion or enhancing gastric motility. The composition is preferably a food composition.

The present application relates to the technical field of veterinary medicine preparation, and particularly relates to a water-soluble medicine gastro-resistant and enteric-coated granule, a preparation method and application thereof, the coated granule comprising: an inner core of at least one water-soluble medicine active ingredient, a coating layer coated outside the inner core; and the coating layer is formed by a composite coating material of hydrogenated palm oil and lipophilic hydrophobic nano active light calcium carbonate. The present application has the advantages that the nano calcium carbonate is used to form pores in the true stomach by acid reaction and to produce gas by saponification with fatty acids in the intestinal tract, so that the water-soluble medicine is efficiently protected in the rumen and rapidly and completely released in the intestinal tract. In vitro tests show that the effective release rate can reach more than 79%, which is significantly better than the traditional coating, and has a broad clinical application prospect.

The present invention provides NOS inhibitors such as iNOS inhibitors including alkylamine or heteroalkylamine derivatives, or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, hydrate, or isomer thereof, in any crystalline form or in amorphous form. Pharmaceutical products comprising the NOS inhibitors such as iNOS inhibitors and the applications thereof in prophylaxis and / or treatment of inflammatory diseases, and proliferative diseases such as cancer including gastro-intestinal, colorectal, gynecological, pancreatic, head and neck, esophageal, breast, lung, and central nervous system tumors, among others, are also provided.

The invention relates to an anchor (14) for an implant (20) for use in the gastro-intestinal tract. The anchor (14) comprises a tissue contact portion (16) with a bedding region (16a). The bedding region (16a) is configured to at least partly integrate into, or to promote integration into, a wall of the gastro-intestinal tract.

The present application relates to a kind of amoxicillin gastric retention sustained-release preparation, which contains amoxicillin, sustained-release material, swelling agent and other pharmaceutical adjuvant, preferably also contains stabilizer or ion regulator.The combination of the above-mentioned adjuvant can be retained in the stomach for up to 24 hours, the complete release time is 10-24h, which can significantly prolong the retention time of amoxicillin in the stomach, has the advantages of fast floating, high effective concentration of drug in the stomach, long stable concentration time, and is beneficial to reduce the frequency of drug administration of patients;Further preferably, it is made into a double-layer tablet containing immediate-release layer, which can quickly reach effective concentration and also can be released slowly and continuously, maintaining effective concentration for a long time;When combined with proton pump inhibitors such as vonolabian, etc., combination kit or compound, only 1-2 times per day is needed, which can further improve the therapeutic effect and patient compliance.

This invention discloses an extracellular vesicle derived from Gastrodia elata, its preparation method, and its use in preparing drugs for treating glaucoma, belonging to the field of biomedical technology. This invention claims protection for an extracellular vesicle prepared from dried Gastrodia elata. The extracellular vesicles provided by this invention have no significant cytotoxicity and good biocompatibility. Studies have shown that these extracellular vesicles can significantly inhibit apoptosis of R28 cells and loss of Brn3a⁺ cells in the mouse retina in a glutamate excitotoxicity model. In a glaucoma model, these extracellular vesicles can effectively protect the survival of retinal ganglion cells (RGCs) and retinal function, and can significantly reduce retinal neuroinflammatory responses in the glaucoma model. Therefore, the extracellular vesicles provided by this invention have a clear anti-glaucoma-related retinal damage effect and possess great potential for development into drugs for treating glaucoma.

One or more devices, systems, methods, and storage mediums for performing robotic control, correction, adjustment, and / or smoothing for a continuum robot are provided herein. Examples of such control, correction, adjustment, and / or smoothing include, but are not limited to, correction of one or more sections or portions of a continuum robot as the continuum robot is moved, state transition(s) or change(s), and path smoothing for a continuum robot. Examples of applications include imaging, evaluating, and diagnosing biological objects, such as, but not limited to, for Gastro-intestinal, cardio, bronchial, and / or ophthalmic applications, and being obtained via one or more optical instruments, such as, but not limited to, optical probes, catheters, endoscopes, and bronchoscopes. Techniques provided herein also improve processing and imaging efficiency while achieving images that are more precise, and also achieve devices, systems, methods, and storage mediums that reduce mental and physical burden and improve ease of use.

The invention discloses a traction capsule stomach tube and a using method thereof, and the traction capsule stomach tube comprises an instant capsule shell which is made of water-soluble food-grade gelatin and can be dissolved in the stomach; a thin hole is formed in the near end side of the instant capsule shell; a channel with two open ends is formed in the film stomach tube; a plurality of side holes are formed in the far-end side of the thin-film stomach tube in a staggered mode, and a cutting line is arranged on the near-end side of the thin-film stomach tube. The thin-film stomach tube can be coiled and folded; the guide ball head wraps the far-end side of the thin-film stomach tube and enables the far-end side opening of the thin-film stomach tube to be kept in an open state; the guide ball head is made of a water-soluble hard candy ball and can be dissolved in the stomach, and the dissolving time of the guide ball head is longer than that of the instant capsule shell; the prompter is arranged on the near-end side of the thin-film stomach tube, and the position where the thin-film stomach tube reaches is prompted through color changes generated by the acid-base reaction.

This description relates to gastro-resistant controlled-release dosage forms comprising Compound (I): (see Formula) (I), or a pharmaceutically acceptable salt and / or solvate thereof, the pharmacokinetic properties of these dosage forms, and their preparation. The novel dosage forms described herein are useful for reducing the risk of QT prolongation in a subject and for treating a disorder in a subject in need, e.g., a subject diagnosed with schizophrenia, for example, in the treatment of negative symptoms in a subject diagnosed with schizophrenia who has the CYP2D6 EM genotype.

The present invention relates to a gastro resistant capsule comprising one or more proteases. wherein the capsule shell comprises a water-soluble film forming polymer and a water-soluble enteric polymer. The present invention also relates to methods of manufacturing the gastro resistant capsules and uses thereof.

The present invention provides non-invasive intraoral devices and methods for the detection of intraoral acid exposure, methods of making said devices, and their use in the diagnosis of disorders such as gastro-oesophageal reflux disease (GORD).

This disclosure relates to gastro-resistant, controlled release dosage forms comprising Compound (I): (I), or a pharmaceutically acceptable salt and / or solvate thereof, the pharmacokinetic properties of these dosage forms, and the preparation of the same. The novel dosage forms disclosed herein are useful in reducing the risk of QT prolongation in a subject and in treating a disorder in a subject in need thereof, e.g., a subject diagnosed with schizophrenia, for example, in treating the negative symptoms in a subject diagnosed with schizophrenia having the CYP2D6 EM genotype.

A gastro-resistant nutraceutical composition is described, comprising a pomace extract (preferably of the Aglianico cultivar), rich in polyphenols, microencapsulated in maltodextrins (MaGPE), preferably in combination with vitamin B2, vitamin A and zinc, and the use thereof to counteract age-related macular degeneration.

A gastro-resistant nutraceutical composition is described, comprising a pomace extract (preferably of the Aglianico cultivar), rich in polyphenols, microencapsulated in maltodextrins (MaGPE), preferably in combination with vitamin B2, vitamin A and zinc, and the use thereof to counteract age-related macular degeneration.

The invention relates to a predictive gene expression signature of response to antiangiogenic drugs, such as axitinib, in gastro-enteric-pancreatic and pulmonary neuroendocrine tumours. The signature is formed by the gene expression of three genes (SPP1, ATXN7 and REXO1L2P), which is converted by means of a bioinformation packet into a unique score that can predict which patients will benefit from treatment with the drug, this benefit being understood as longer survival without progression and larger tumour volume reductions in response to treatment.

Devices and methods for deploying an anastomotic stent between portions of the gastro-intestinal (GI) tract are disclosed. The anastomotic stents are configured to atraumatically engage the tissue walls and to permit the flow of fluid, partially digested food, and food. The stents can be deployed using endoscopic catheter devices, laparoscopic tools, and combinations of both endoscopic tools and laparoscopic tools. Examples of anastomoses include anastomoses between the stomach and a portion of the intestines such as the jejunum. Anastomoses can also be formed between two closed ends of the intestines, such as two closed ends of the colon formed during a colon resection procedure. Anastomoses can also be formed between a fundal pouch formed during a gastric bypass procedure and the jejunum. Laparoscopic tools are disclosed to deploy a stent by selectively removing a radial restraint on a self expanding stent with the restraint removed through the laparoscopic access points.

The invention relates to the field of biological medicine, in particular to a CD66c-targeted antibody coupling medicine and application thereof in preparation of a medicine for treating gastroesophageal junction cancer, the structure of the antibody coupling medicine is shown as follows: Ab-(L-D) n, Ab is an anti-CD66c antibody, the anti-CD66c antibody is selected from a full-length antibody or an antibody fragment, L is a connexon, n is a positive integer, and n is a positive integer. The linker is selected from a non-breakable linker or a breakable linker; d is a cell toxic agent, the cell toxic agent is selected from toxins, chemotherapeutics, antibiotics, radioisotopes or growth inhibitors, and n is an integer from 1 to 40. The CD66c is found to be a novel gastro-esophageal junction cancer ADC target spot, meanwhile, the synthesized CD66c-DXd ADC is proved to have a remarkable killing effect on the gastro-esophageal junction cancer at the in-vivo and in-vitro levels, and a promising targeted therapy candidate drug is provided for targeted therapy of the gastro-esophageal junction cancer.

Provided herein are controlled release gastroretentive dosage forms containing deuterated tetrabenazine for use in the treatment of e.g. Hyperactivity dyskinesia. The dosage form provides advantageous pharmacokinetic profiles when orally administered to a subject once a day.

This invention relates to the field of intelligent medical device technology, specifically to an intelligent health patch system and its control method based on gastro-brain axis communication. The system includes an intelligent patch integrating a multimodal physiological sensing module for collecting gastric electrical signals and heart rate variability signals, and a biomimetic control execution module for performing transcutaneous electrical stimulation and tactile feedback; a mobile computing terminal configured with a gastro-brain axis state assessment model for evaluating the user's hunger drive level based on the physiological signals, and a personalized control decision engine for generating control instructions. The mobile computing terminal can, based on the output of the assessment model, achieve non-invasive closed-loop control of the gastro-brain axis: for the first time, closed-loop management of "ascending signal sensing" and "descending neural control" of the gastro-brain axis is realized on a consumer-grade wearable patch, making the intervention more physiologically targeted and scientific.

The present invention relates to the use of human milk oligosaccharides for feeding production animals such as calves. The present invention further relates to milk replacer compositions containing human milk oligosaccharides. Further subject matter of the present invention is a method for preventing and treating gastrointestinal diseases, particularly gastro-intestinal infections, of young production animals, in particular calves, by administering an effective amount of one or more human milk oligosaccharides. Particularly useful in the context of the present invention as one or the human milk oligosaccharide is 2'-fucosyllactose (2-FL).